Marshall Wace
TEVA icon

Marshall Wace’s Teva Pharmaceuticals TEVA Stock Holding History

Marshall Wace’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,700
Closed -$240K – 3667
2025
Q4 		$240K Buy
7,700
+2,700
+54% +$66.5K ﹤0.01% 2532
2025
Q3 		$101K Buy
+5,000
New +$87.8K ﹤0.01% 2660

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's TEVA Position: Q1 2025 in Review

Marshall Wace sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 5,155,402 shares — an estimated $114M sold.

Marshall Wace first reported a position in TEVA in Q1 2014 and held it in 24 quarters. The position peaked at $114M in Q4 2024. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Marshall Wace reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Marshall Wace sold 5,155,402 Teva Pharmaceuticals shares in Q1 2025, an estimated $114M.
  • Marshall Wace first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 24 quarters.
  • Marshall Wace's Teva Pharmaceuticals position peaked at $114M in Q4 2024.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Marshall Wace's 13F filing for Q1 2025, filed 15 May 2025.